BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intrexon Corporation Prices Initial Public Offering


8/8/2013 6:54:54 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Intrexon Prices Initial Public Offering

GERMANTOWN, Md.
, Aug. 7, 2013 /PRNewswire/ -- Intrexon Corporation today announced the pricing of its initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and offering expenses. All of the common stock is being offered by Intrexon. The shares are expected to begin trading on the New York Stock Exchange on Thursday, August 8, 2013, under the symbol "XON."

In addition, Intrexon has granted the underwriters a 30-day option to purchase up to 1,499,999 additional shares of common stock from Intrexon.

J.P. Morgan and Barclays are acting as joint book-running managers for the offering. Griffin Securities and Mizuho Securities are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 7, 2013. When available, you may request a copy of the final prospectus relating to this offering by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (866) 803-9204 or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intrexon Corporation
Intrexon Corporation is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.

For more information regarding Intrexon Corporation, contact:

Corporate Contact:


Investor Contact:

Peter McLaughlin


The Ruth Group

Vice President, Corporate Communications


Nick Laudico

Intrexon Corporation


Tel: 646-536-7030

Tel: +1 (323) 842-7779


nlaudico@theruthgroup.com

pmclaughlin@intrexon.com



SOURCE Intrexon Corporation



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES